Dermama Bioteknologi Laboratorium
Indonesia - SurakartaBiotechnology
Focus: Dermama Bioteknologi Laboratorium is an Indonesian biotechnology company focused on regenerative therapies, operating from Surakarta since 2006. As a public-stage firm, it maintains a focused pipeline in advanced cell and exosome-based therapeutics.
Profile data last refreshed Yesterday · AI intelligence enriched 2w ago
Funding Stage
PUBLIC
Open Jobs
0
About Dermama Bioteknologi Laboratorium
AI assessmentNot HiringNo open roles listed right now. Follow Dermama Bioteknologi Laboratorium to get notified when they start hiring — the background below is worth knowing for when they do.
Why Work Here
Data completeness
1/9 — Limited
Company HealthSolid
Pipeline
Early-stage
1 total
LOE Risk
Protected
No near-term cliffs
Hiring
0 open
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
Exosome-MSC Intravenous injection
SARS-CoV2 InfectionClinical Trials (1)
NCT05216562Efficacy and Safety of EXOSOME-MSC Therapy to Reduce Hyper-inflammation In Moderate COVID-19 Patients
Phase 2/3Help build intelligence for Dermama Bioteknologi Laboratorium
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.